Long-term morphological and functional evaluation of the neuroprotective effects of post-ischemic treatment with melatonin in rats

Journal of Pineal Research

Volumn 42, Issue 2, 2007, Pages 138-146

  Letechipía Vallejo, Graciela ^b   López Loeza, Elisa ^a,b   Espinoza González, Verónica ^b   González Burgos, Ignacio ^a,b   Olvera Cortés, María Esther ^a   Moralí, Gabriela ^c   Cervantes, Miguel ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Antioxidant; Cognitive performance; Global cerebral ischemia; Melatonin; Neuroprotection

Indexed keywords

MELATONIN; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPUS; MALE; MAZE TEST; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PYRAMIDAL NERVE CELL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; WORKING MEMORY; ANIMAL; PATHOLOGY;

ANIMALS; BRAIN ISCHEMIA; MALE; MELATONIN; NEUROPROTECTIVE AGENTS; RATS;

EID: 33846934248     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2006.00395.x     Document Type: Article

References (52)

1. KIRINO T, TAMURA A, SANO K. Selective vulnerability of the hippocampus to ischemia-reversible and irreversible types of ischemic cell damage. In: Progress in Brain Research. Vol. 63. Molecular Mechanisms of Ischemic Brain Damage. Kogure K, Hossman KA, Siesjö BK, Welsh FA, eds. Elsevier, New York, 1985; pp. 39-58.
2. PULSINELLI WA. Selective neuronal vulnerability: morphological and molecular characteristics. In: Progress in Brain Research. Vol. 63. Molecular Mechanisms of Ischemic Brain Damage. Kogure K, Hossman KA, Siesjö BK, Welsh FA, eds. Elsevier, New York, 1985; pp. 29-37.
3. LIPTON P. Ischemic cell death in brain neurons. Physiol Rev 1999; 79:1431-1560.
4. SARRAF-YAZDI S, LASKOWITZ D, WARNER DS. Pathophysiology of ischemic brain damage. In: Management of Acute Stroke. Shuaib A, Goldstein LB, eds. Marcel Decker, New York, 1999; pp. 243-277.
5. BRAMLET HM, DIETRICH D. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab 2004; 24:133-150.
6. KOGURE K, ARAI H, ABE K, NAKANO M. Free radical damage of the brain following ischemia. In: Progress in Brain Research. Vol. 63. Molecular Mechanisms of Ischemic Brain Damage. Kogure K, Hossman KA, Siesjö BK, Welsh FA, eds. Elsevier, New York, 1985; pp. 237-259.
7. KITAGAWA K, MATSUMOTO M, ODA T et al. Free radical generation during brief period of cerebral ischemia may trigger delayed neuronal death. Neuroscience 1990; 35:551-558.
8. TRAYSTMAN RJ, KIRSCH JR, KOEHLER RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 1991; 71:1185-1195.
9. CHAN PH. Role of oxidants in ischemic brain damage. Stroke 1996; 27:1124-1129.
10. CHAN PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001; 21:2-14.
11. MARGAILL I, PLOTKINE M, LEROUET D. Antioxidant strategies in the treatment of stroke. Free Radic Biol Med 2005; 39:429-433.
12. REITER RJ, ACUÑA-CASTROVIEJO D, TAN DX et al. Free radical mediated molecular damage: mechanisms of melatonin's protective actions in the central nervous system. Ann N Y Acad Sci 2001; 939:200-215.
13. TAN DX, CHEN LD, POEGGELER B et al. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
14. REITER RJ, TAN DX, OSUNA C et al. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 2000; 7:444-458.
15. CUZZOCREA S, COSTANTINO G, GITTO E et al. Protective effects of melatonin in ischemic brain injury. J Pineal Res 2000; 29:217-227.
16. LETECHIPIA-VALLEJO G, GONZALEZ-BURGOS I, CERVANTES M. Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats. Arch Med Res 2001; 32:186-192.
17. CHEUNG RTF. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 2003; 34:153-160.
18. REITER RJ, TAN DX, LEON J et al. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med 2005; 230:104-117.
19. BARLOW-WALDEN LR, REITER RJ, ABE M et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26:497-502.
20. EL-ABHAR HS, SHAALAN M, BARAKAT M, EL-DENSHARY ES. Effect of melatonin and nifedipine on some antioxidant enzymes and different energy fuels in the blood and brain of global ischemic rats. J Pineal Res 2002; 33:87-94.
21. RODRIGUEZ C, MAYO JC, SAINZ RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1-9.
22. MARTIN M, MACIAS M, ESCAMES G et al. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000; 28:242-248.
23. JOU MJ, PENG TI, REITER RJ et al. Visualization of the effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 2004; 37:55-70.
24. LEON J, ACUÑA-CASTROVIEJO D, ESCAMES G et al. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005; 38:1-9.
25. REITER RJ, SAINZ RM, LOPEZ-BURILLO S et al. Melatonin ameliorates neurological damage and neurophysiological deficits in experimental models of stroke. Ann N Y Acad Sci 2004; 993:35-47.
26. MACLEOD MR, O'COLLINS T, HORMY LI et al. Systematic review and meta analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 2005; 38:35-41.
27. BARONE FC, FEVERSTEIN GS. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19:819-834.
28. FINKLESTEIN SP, FISHER M, FURLAN AJ et al. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30:2752-2758.
29. OLSEN GM, SCHEEL-KRÜGER J, MOLLER A, JENSEN LF. Relation of spatial learning of rats in the Morris water maze task to the number of viable CA1 neurons following fourvessel occlusion. Behav Neurosci 1994; 108:681-690.
30. BLOCK F. Global ischemia and behavioural deficits. Prog Neurobiol 1999; 58:279-295.
31. ZOLA-MORGAN S, SQUIRE LR, AMARAL DG. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986; 6:2950-2967.
32. LIM C, ALEXANDER MP, LAFLECHE G et al. The neurological and cognitive sequelae of cardiac arrest. Neurology 2004; 63:1774-1778.
33. HARTMAN RE, LEE JM, ZIPFEL GJ, WOZNIA DF. Characterizing learning deficits and hippocampal neuron loss following transient global cerebral ischemia in rats. Brain Res 2005; 1043:48-56.
34. PULSINELLI WA, BRIERLEY JB. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 1979; 10:267-272.
35. PULSINELLI WA, BUCHAN AM. The four-vessel occlusion rat model: methods for complete occlusion of vertebral arteries and control of collateral circulation. Stroke 1988; 19:913-915.
36. MORRIS RGM. Development of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11:47-60.
37. OLTON DS. The radial arm maze as a tool in behavioral pharmacology. Physiol Behav 1987; 40:793-797.
38. LUNA G. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology, 3rd edn. McGraw-Hill, New York, 1960.
39. PAXINOS G, WATSON C. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, San Diego, CA, 1986.
40. SIEGEL S. Nonparametric Statistics for the Behavioral Sciences. McGraw-Hill, New York, 1956.
41. DOWNIE MM, HEATH RW. Basic Statistical Methods. Harper E Row, New York, 1983.
42. GREEN AR, CROSS AJ. Techniques for examining neuroprotective drugs in vivo. In: Progress in Brain Research. Vol. 40. Neuroprotective Agents and Cerebral Ischemia. Green AR, Cross AJ, eds. Academic Press, New York, 1997; pp. 47-68.
43. PALMER GE, CREGAN EF, BORRELLI AR, WILLETT F. Neuroprotective properties of the uncompetitive NMDA receptor antagonist ramacemide hydrochloride. Ann N Y Acad Sci 1995; 765:236-247.
44. CHO S, JOH TH, BAIK HH et al. Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats. Brain Res 1997; 755:335-338.
45. BENITEZ-KING G, ORTIZ-LOPEZ L, JIMENEZ-RUBIO G. Melatonin precludes cytoskeletal collapse caused by hydrogen peroxide: participation of protein kinase C. Therapy 2005; 2:767-778.
46. BENITEZ-KING G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006; 40:1-9.
47. MCDONALD RJ, WHITE NM. A triple dissociation of memory systems: hippocampus. Behav Neurosci 1993; 107:3-22.
48. MCNAMARA RK, SKETTON RW. The neuropharmacological and neurochemical bases of place learning in the Morris water maze. Brain Res Rev 1993; 18:33-49.
49. SILVA AJ, GIESE KP, FEDOROV NB et al. Molecular, cellular, and neuroanatomical substrates of place learning. Neurobiol Learn Memory 1998; 70:44-61.
50. OLVERA-CORTES E, CERVANTES M, GONZALEZ-BURGOS I. Place learning but not cue-learning modifies the hippocampal theta rhythm in rats. Brain Res Bull 2002; 58:261-270.
51. FLORESCO SB, SEAMANS JK, PHILLIPS AG. Selective roles for hippocampal, prefrontal cortical, and ventral striatal circuits in radial arm maze tasks with or without delay. J Neurosci 1997; 17:1880-1890.
52. LAROCHE S, DAVIS S, JAY TM. Plasticity at hippocampal to prefrontal cortex synapses: dual roles in working memory and consolidation. Hippocampus 2000; 10:438-446.